Literature DB >> 16356341

A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation.

Jason Sklerov1, Barry Levine, Karla A Moore, Theodore King, David Fowler.   

Abstract

A case of a 25-year-old white male who was found dead the morning after consuming herbal extracts containing beta-carbolines and hallucinogenic tryptamines is presented. No anatomic cause of death was found at autopsy. Toxicologic analysis of the heart blood identified N,N-dimethyltryptamine (0.02 mg/L), 5-methoxy-N,N-dimethyltryptamine (1.88 mg/L), tetrahydroharmine (0.38 mg/L), harmaline (0.07 mg/L), and harmine (0.17 mg/L). All substances were extracted by a single-step n-butyl chloride extraction following alkalinization with borate buffer. Detection and quantitation was performed using liquid chromatography-electrospray mass spectrometry. The medical examiner ruled that the cause of death was hallucinogenic amine intoxication, and the manner of death was undetermined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16356341     DOI: 10.1093/jat/29.8.838

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  32 in total

Review 1.  Modern instrumental methods in forensic toxicology.

Authors:  Michael L Smith; Shawn P Vorce; Justin M Holler; Eric Shimomura; Joe Magluilo; Aaron J Jacobs; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2007-06       Impact factor: 3.367

2.  The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Authors:  Alan K Davis; Joseph P Barsuglia; Rafael Lancelotta; Robert M Grant; Elise Renn
Journal:  J Psychopharmacol       Date:  2018-04-30       Impact factor: 4.153

3.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

4.  Development of a LC-MS/MS method to analyze 5-methoxy-N,N-dimethyltryptamine and bufotenine, and application to pharmacokinetic study.

Authors:  Hong-Wu Shen; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Bioanalysis       Date:  2009-04       Impact factor: 2.681

5.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

6.  Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.

Authors:  C William Heise; Daniel E Brooks
Journal:  J Med Toxicol       Date:  2016-11-28

7.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

8.  Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.

Authors:  Hong-Wu Shen; Chao Wu; Xi-Ling Jiang; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2010-03-03       Impact factor: 5.858

9.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

10.  Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Donald E Mager; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2013-02-07       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.